Untitled-2

Sri Adichunchanagiri College of Pharmacy
Department of Clinical Pharmacy, Adichunchanagiri Hospital & Research Centre, B.G.Nagara, Karnataka- 571448 www.accp.co.in, [email protected]; Phone: 08234 287055 Ext: 250; 08234 287590 (SACCP)
DRUG INFOS- Online Drug Information Center; 08234-290234, [email protected]
Editorial Board: Dr. B Ramesh, Dr. Rajesh Venkataraman, Mr. B.P Satish Kumar, Mr. M Kumaraswamy, Dr. Rajveer Singh Chopra
Sri Adichunchanagiri College of Pharmacy is the premier educational institution in Pharmaceutical Sciences. The institution is under the aegis of Sri Adichunchanagiri Shikshana Trust under the leadership of Sri Sri Sri Nirmalanandanatha Swamiji. Now the institution is offering; D.Pharm, B.Pharm, M. Pharm, Pharm D and Pharm D (Post Baccalaureate) courses, approved by AICTE, PCI & Affiliated to RGUHS Bangalore.
Grape Juice Mixed With Some Prescription Drugs Can
Be Hazardous
Eating grapefruit can be dangerous for people taking amlodipine, apixaban, cilostazol, clopidogrel, certain prescription medications, but many doctors are dronedarone, elerenone, ergotamine, Felodipine, unaware of the risks. The Lawson Health Research losartan, manidipine, nicardipine, nifedipine, nimodipine, Institute in London, Canada has studied the effects of nisoldipine, nitrendipine, propafenone, quinidine, mixing grapefruit juice with prescription drugs for rivaroxaban, sibutramine, sildenafil, tadalafil, ticagrelor, decades. As recently as 2008, they had a list totaling 17 vardenafil, aprepitant, alfentanil-oral, buspirone, medications that shouldn't be taken with the juice. Their carbamazepine, dextromethorphan, diazepam, fentanyl- current findings have now upped that number to 44 oral, fluvoxamine, ketamine-oral, lurasidone, methadone, drugs. Experts explain that certain medications react midazolam,-oral, oxycodone, pimozide, quazepam, adversely to grapefruit juice by processing in your body at quetiapine, sertraline, triazolam, ziprasidone, estradiol, a faster rate. While this may sound harmless, researchers ethinylestradiol, cisapride, domperidone, cyclosporine, say it actually creates a significant increase in the drug's everolimus, sirolimus, tacrolimus, darifenacin, potency. In some cases, the strength of certain medicines festerodine, solifenacin, silodosin, tamsulosin.
can be raised to a point equivalent to the patient getting double the dose with each pill.Here are the drugs that The research team also said the effects of combining researchers said should not be taken with grapefruit juice: grapefruit juice with certain medications varies in severity, so patients taking one of the listed drugs should speak to Crizotinib, cyclophosphamide, dasatinib, erlotinib, their doctor about the specific effects of their particular everrolimus, imatinib, lapatinib, nilotinib, pazopanib, medicine. The study also showed that some drugs sorafenib, sunitinib, vandetanib, venurafenib, increase in potency with the citrusy juice, while other repaglinide, saxagliptin, albendazole, artemether, drugs are weakened. In addition, the combination of the erythromycin, etravirine, halofantrine, maraviroc, juice with certain medicines can bring about skin rashes, praziquantel, primaquine, quinine, rilpivirine, saquinivir, dizziness, headaches, breathing troubles and a number budesonide-oral, colchicine, methylprednisolone-oral, atorvastatin, lovastatin, simvastatin, amiodarone, We acknowledge, the Doctors of Adichunchanagiri Hospital and Research Center for
their constant support.
FDA Drug Safety Communication: Risk of next-morning impairment
after use of insomnia drugs
ISSUE: FDA is notifying the public of new information about
BACKGROUND: Zolpidem is a sedative-hypnotic (sleep)
zolpidem, a widely prescribed insomnia drug. FDA medicine used in adults for the treatment of insomnia. recommends that the bedtime dose be lowered because RECOMMENDATION: FDA urges health care professionals new data show that blood levels in some patients may be to caution all patients (men and women) who use these high enough the morning after use to impair activities that products about the risks of next-morning impairment for require alertness, including driving. This announcement activities that require complete mental alertness, including focuses on zolpidem products approved for bedtime use. Women appear to be more susceptible to this risk because they eliminate zolpidem from their bodies more slowly than • The recommended dose of zolpidem for women should be lowered from 10 mg to 5 mg for immediate-release products and from 12.5 mg to 6.25 mg for extended- Because use of lower doses of zolpidem will result in lower blood levels in the morning, FDA is requiring the • For zolpidem and other insomnia drugs, prescribe the manufacturers of Ambien, Ambien CR, Edluar, and Zolpimist lowest dose that treats the patient's symptoms.
• Inform patients that impairment from sleep drugs can be FDA is continuing to evaluate the risk of impaired mental present despite feeling fully awake.
alertness with other insomnia drugs, including over-the-counter (OTC) drugs available without a prescription.
FDA Pushing to Eliminate Most Prescriptions; Make Majority of Drugs
Over-The-Counter
The FDA is considering a new prescription program also Although the FDA has not yet decided how to expand access referred to as the "New Paradigm" that would enable certain of certain prescription medications, one key element of their prescription drugs to be available without a prescription if proposal surrounds a pharmacist-driven patient care they met certain criteria that ensured "conditions of safe use." program that would likely involve patient counseling, patient The program would involve a variety of medications that treat monitoring, drug interaction prevention and simple so-called "common conditions" (i.e. hypertension, diabetes, diagnostic testing. Another element of the proposal, elevated cholesterol, migraine headaches, asthma, flu, suggested by the FDA, may involve having a physician allergies, smoking cessation etc.) The FDA's apparent prepare the initial prescription for the medication with rationale behind this proposal is based on evidence from the subsequent access to the medication without a prescription National Journal that shows that people in the U.S. have poor if "conditions of safe use" are met. Lastly, the FDA believes medication adherence due to a variety of factors (i.e. costs, various technologies like pharmacy-based kiosks or internet time, need for multiple physician visits, lack of a prescription based questionnaires may help support their proposal by drug plan and so on) that ultimately hamper the prescription helping patients properly self-diagnose and select the and medication renewal processes. In addition, the FDA appropriate medication(s) for their condition(s).
believes that these factors dissuade a person from taking potentially lifesaving medications which further contributes to the under-treatment of common medical condition.
Chemicals Found In Bee Stings Could Help Prevent The Spread of HIV
Scientists at Washington University School of Medicine in St. rampant spread of HIV, which causes AIDS.
Louis believe that chemicals found in bee stings can destroy the virus, preventing it from becoming AIDS. According to The bees' chemical, melittin, destroys the HIV virus by the Midwestern school's doctors the nanoparticles carrying puncturing its protective outer layer. Scientists inserted the the toxin -- called melittin -- destroys HIV, while leaving toxin into tiny nano particles, which are fitted with special “bumpers” so they can off normal cells. But when the smaller HIV virus makes contact with them, it slips between the Scientists are excited by the find and believe it could be an bumpers and is attacked by the toxin.
important step towards developing a gel to stem the NEW DRUG PROFILE – ALOGLIPTIN
Indications
is 25/2000mg. It comes as a tablet to take by mouth This medication is an anti-diabetic drug, prescribed for (1.2.5/500mg), two times per day with food.
Warnings and Precautions : * Caution should be
Contraindications:
exercised in patients with history of liver impairment, acute Contraindicated in patients with kidney impairment, pancreatitis, any allergy, who are taking other medications, metabolic acidosis, diabetic ketoacidosis, and elderly, children, during pregnancy and breastfeeding. * Patient may develop with increased risk of liver failure (sometimes fatal); monitor liver functions and complete Pregnancy Category
blood counts regularly while taking this medication. Category B : Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate Mechanism of Action
and well-controlled studies in pregnant women OR Animal Alogliptin is a small-molecule, orally available dipeptidyl studies have shown an adverse effect, but adequate and peptidase IV (DPP IV) inhibitor. DPP-4 inhibitors slow the well-controlled studies in pregnant women have failed to inactivation of incretin hormones GLP-1 (glucagon-like demonstrate a risk to the fetus in any trimester.
peptide-1) and GIP (glucose-dependent insulinotropic peptide), both of which play a role in regulating blood Dosage & When it is to be taken: PO - The initial dose is based on patient's condition. Maximum recommended dose DRUGS APPROVED BY CDSCO DURING Jan - Mar 2013
Name of Drug
Indication
Date of issue
Diclofenac Diethylamine BP 2.32 % w/v Eq to Diclofenac Sodium 2.00 % w/v + Methyl Salicylate IP 10.00% w/v + Menthol 5.00 % w/v + Absolute Alcohol IP 10.00 % v/v Topical Solution (Additional Strength) Telmisartan 20mg + Amlodipine Besylate Eq. to Amlodipine 2.5mg + Hydrochlorothizide 6.25mg Amlodipine besilate IP Eq. to Amlodipine 10mg + Indapamide SR 1.5 mg Ta b l e t ( A d d i t i o n a l For the treatment of patients with myelofibrosis including primary myelofibrosis, post-polycythemia v e r a m y e l o f i b r o s i s o r p o s t- e s s e n t i a l t h r o m b o c y t h e m i a myelofibrosis.
DEPARTMENT ACTIVITIES
Department Activities
DRUG INFOS
“We strive in serving the Medical fraternity” ACTIVITIES DURING JAN - MAR 2013
Total Online Drug Informations Given: 45
Department
No. of Queries
DEPARTMENT NEWS
Online Drug Information Centre (ODIC) was inaugurated on 24th January 2013 by
the Department of Pharmacy Practice in association with Adichunchanagiri Hospital &
Research Center, B.G.Nagara. The programme Inaugurated by Dr. T.M Manohar,
Medical Superintendent, AH&RC continued with welcome note by Dr. B.Ramesh,
Principal, SACCP.A talk on “Need for Drug Infos – Current Scenario” by
Mr.Samson.P.George, Drug Information Pharmacist, Drug Information Centre KSPC,
Karnataka. Intorduction to ODIC by Dr.Rajesh.V, Associate Professor & Head,
Department of Pharmacy Practice and Manager Drug Infos.
Following Eminent Personalities specialized in the field of Pharmacy Practice professionalized the one day work shop organized by the college on “Core Values of Clinical Pharmacist in Health Care”. Dr. M.S.Ganachari, Professor & Head, Department of Pharmacy Practice, KLE’S College of Pharmacy, Belgaum Dr. B.J.Mahendra Kumar, Professor & Head Department of Pharmacy Practice, JDT Islam College of Pharmacy, Kerela Dr. P.K.Manna, Professor of Pharmacy, Annamalai University, Tamil Nadu Dr. Anand B. Harugeri , Patient Safety Manager, Astra Zeneca Pharma India Ltd.
Dr. Geeta Kishore, Professor & Head, Department of Pharmacy Practice, KIMS, Bangalore Dr. Shobha Rani R H, Professor & Head, Department of Pharmacy Practice, Al-Ameen College of Pharmacy, Bangalore.
Sri Adichunchanagiri College of Pharmacy
B.G Nagara - 571448, Karnataka.
Ph : 08234-287870, 287590 (Telefax)
Mob: +91 9845863779 (Principal)
e-mail : [email protected]
web: www.accp.co.in

Source: http://www.accp.co.in/issue1.pdf